Provide feedbackProvide feedback
Home :: Ophthalmology

Ranibizumab plus laser treatment may offer new option for treating diabetic macular edema, new research shows

Monday, May 10 2010 | Comments
Evidence Grade 1 What's This?

The combination of ranibizumab injections and prompt or deferred laser treatment may be more effective in treating diabetic macular edema at least through 1 year relative to laser treatment alone, according to new Phase III data. The trial included 691 patients (mean age, 63 years) with type 1 or type 2 diabetes and diabetic macular edema involving the central macula. Most of the patients had 1 eye treated, but 24% had both eyes treated. Researchers randomized 854 eyes to 1 of 4...

The combination of ranibizumab injections and prompt or deferred laser treatment may be more effective in treating diabetic macular edema at least through 1 year relative to laser treatment alone, according to new Phase III data.

The trial included 691 patients (mean age, 63 years) with type 1 or type 2 diabetes and diabetic macular edema involving the central macula.

Most of the patients had 1 eye treated, but 24% had both eyes treated. Researchers randomized 854 eyes to 1 of 4 study groups: sham injections plus prompt focal/grid laser treatment within 1 week (n=293), ranibizumab injections plus prompt laser treatment (n=187), ranibizumab injections plus laser treatment deferred for at least 6 months (n=188), or triamcinolone acetonide injections plus prompt laser treatment (n=186).

The study team planned follow-up for 3 years, assessing the primary outcome of change in visual acuity from baseline at 1 year. Data were reported through Feb. 8, 2010, and included >=1 year of follow-up for 799 eyes and 2 years of follow-up for 484 eyes.

At 1 year, the visual acuity letter score increased from baseline by an average of 9 points for both of the ranibizumab groups; these improvements were significantly greater than the mean increase recorded in the sham injection plus laser group (3 points). The triamcinolone plus prompt laser group experienced a mean increase of 4 points in the visual acuity letter score.

Approximately 20% of both ranibizumab groups had a 10 to 14 letter improvement from baseline, which is equivalent to 2 lines on the eye chart, compared with 12% of the triamcinolone plus prompt laser group and 13% of the sham injection plus laser group. Thirty percent of the ranibizumab plus prompt laser group and 28% of the ranibizumab plus deferred laser group had an improvement of >=15 letters, which is equivalent to 3 lines on the eye chart.

The researchers noted that the 2-year outcomes generally mirrored the 1-year primary outcome results.

The study also showed that the ranibizumab groups were superior to the sham plus laser group in terms of retinal thickening at 1 and 2 years. Relative to the laser treatment alone, treatment with triamcinolone plus prompt laser resulted in a greater reduction in retinal thickening at 1 year but not at 2 years.

When the researchers analyzed a subgroup of pseudophakic eyes (n=273), triamcinolone plus prompt laser treatment performed similarly to both ranibizumab groups at improving visual acuity and reducing retinal thickening.

Neither ranibizumab nor triamcinolone were linked with a higher risk of systemic side effects or overall mortality. There was 1 case of progressive traction retinal detachment and 3 cases of injection-related endophthalmitis in the ranibizumab groups, while the triamcinolone group experienced elevated intraocular pressure and cataract surgery more frequently.

The researchers noted that other studies on ranibizumab for diabetic macular edema are under way and these results may further support the role of anti-vascular endothelial growth factor drugs alone or in combination with laser therapy in diabetic macular edema. Still, they stressed that further follow-up on the long-term safety and efficacy of ranibizumab, as well as its cost effectiveness, is necessary.

The investigators added that since 1985, focal/grid photocoagulation laser treatment has been the standard of care for diabetic macular edema. However, the current results revealed that ranibizumab plus laser treatment should be considered for this patient population.

The analysis was published ahead of print April 28 by the journal Ophthalmology by Elman MJ, et al.

This information concerns uses that have not been approved by the Food and Drug Administration.

Latest News

Simvastatin may reduce risk of visual field progression in patients with glaucoma, study reveals Verusmed

Thursday, March 11 2010 | Comments
Evidence Grade 3 What's This?
Simvastatin may have a protective effect with regard to visual field (VF) stabilization in patients with normal tension glaucoma (NTG), according to new evidence.

In the prospective cohort study, researchers followed 256 patients receiving care at the Hong Kong Eye Hospital in China for NTG; follow-up lasted 36 months. Thirty-one patients (12.1%) received simvastatin at a dose of 20 mg to 40 mg, and the other 225...

Pegaptanib may offer alternative therapy for macular edema secondary to BRVO, according to new study Verusmed

Tuesday, February 02 2010 | Comments
Evidence Grade 1 What's This?
Pegaptanib sodium appears to effectively treat macular edema secondary to branch retinal vein occlusion (BRVO), new evidence suggests.

The prospective study included 20 patients aged 50 to 88 years from 3 retinal specialty practice settings who had macular edema secondary to BRVO for more than 1 month but fewer than 6 months. The patients were randomized to receive intravitreous pegaptanib 0.3 mg (n=15) or pegaptanib 1 mg (n=5) at baseline, week 6, and week 12. The patients...


Allergan's Trivaris injections may slow diabetic retinopathy, though laser therapy remains treatment of choice, investigators conclude Verusmed

Wednesday, January 20 2010 | Comments
Evidence Grade 1 What's This?
Allergan Inc.'s corticosteroid Trivaris (trimcinolone acetonide) injectable suspension may reduce the risk of progression of diabetic retinopathy through three years, but use of this treatment cannot be warranted due to adverse events, a new analysis finds.

Researchers conducted an exploratory analysis of a trial by the Diabetic Retinopathy Clinical Research Network, in which 840 eyes from 693 patients (mean age, 63 years) with diabetic...

NHANES data show increased prevalence of vision loss, impairment among adults with diabetes Verusmed

Wednesday, November 19 2008 | Comments
Evidence Grade 9 What's This?
Data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) confirm that vision loss is significantly more common among adults with diabetes than it is among adults without diabetes.

Researchers with the Centers for Disease Control and Prevention used NHANES data to determine the prevalence and correlates of vision impairment among U.S adults with and without diabetes. Based on data from 13,004 survey participants, the...